Impact of depression on health utility value in cancer patients

2015 ◽  
Vol 25 (5) ◽  
pp. 491-495 ◽  
Author(s):  
Daisuke Fujisawa ◽  
Hironobu Inoguchi ◽  
Haruki Shimoda ◽  
Kazuhiro Yoshiuchi ◽  
Shinichiro Inoue ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Health Utility ◽  
Utility Value

Creating a Health Utility Value for Birdshot Chorioretinopathy

2020 ◽  
pp. 1-8
Author(s):  
Anisha Sekaran ◽  
Mohith Shamdas ◽  
Robert J. Barry ◽  
Alastair K. Denniston ◽  
Philip I. Murray
Keyword(s):  
Health Utility ◽  
Utility Value ◽  
Birdshot Chorioretinopathy

scholarly journals Health variations among breast-cancer patients from different disease states: evidence from China

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Qing Yang ◽  
Xuexin Yu ◽  
Wei Zhang
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Cancer Recurrence ◽  
Mapping Function ◽  
Health Utility ◽  
Breast Cancer Patients ◽  
Utility Values ◽  
Disease States

Abstract Background This study aimed to obtain health utility parameters among Chinese breast cancer patients in different disease states for subsequent health economics model. In addition, we aimed to explore the feasibility of establishing a breast cancer health utility mapping model in China. Methods Multiple patient-reported health attributes were assessed, including quality of life, which was measured by the Functional Assessment of Cancer Therapy-Breast (FACT-B) instrument; health utility and self-rated health, which were measured by the EuroQol-5 Dimension-5 Level (EQ-5D-5L) questionnaire. Multivariate regression models, including a linear regression model, an ordinal logistic regression model and a Tobit model, were employed to analyze health differences among 446 breast cancer patients. Subgroup analyses were performed to examine differences in multiple dimensions of health derived from the FACT-B and EQ-5D-5L instruments. A mapping function was used to estimate health utility from quality of life. Rank correlation analyses were employed to examine the correlation between estimated and observed health utility values. Results A total of 446 breast cancer patients with different disease states were analyzed. The health utility values of breast cancer patients in the P state (without cancer recurrence and metastasis), R state (with cancer recurrence within a year), S state (with primary and recurrent breast cancer for the second year and above), and M state (metastatic cancer) were 0.81 (SD ± 0.23), 0.90 (SD ± 0.12), 0.78 (SD ± 0.31), and 0.74 (SD ± 0.27), respectively. There were positive correlations between all scores, including every domain of the FACT-B instrument (p < 0.001). Results from multivariate analysis suggested that patients in the R and M states had lower scores for overall quality of life (R, β = − 9.45, p < 0.01; M, β = − 6.72, p < 0.05). Patients in the M state had lower health utility values than patients in the P state (β = − 0.11, p < 0.05). Estimated health utility values, which were derived from quality of life by using a mapping function, were significantly correlated with directly measured health utility values (p < 0.001). Conclusions We obtained the health utility and health-related quality of life (HRQoL) scores of Chinese breast cancer patients in different disease states. Mapping health utility values from quality of life using four disease states could be feasible in health economic modelling, but the mapping function may need further revision.

Canadian cancer site-specific health utility values: Creating the basis for measuring value and costs of therapy.

2014 ◽  
Vol 32 (30_suppl) ◽  
pp. 7-7 ◽  
Author(s):  
Hiten Naik ◽  
Doris Howell ◽  
Xin Qiu ◽  
Catherine Brown ◽  
Ashlee Vennettilli ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Performance Status ◽  
Health Utility ◽  
Cancer Site ◽  
Specific Reference ◽  
Site Specific ◽  
Utility Values ◽  
Hematologic Cancer ◽  
Routine Administration ◽  
Patient Reported

7 Background: Health utility values (HUVs) play an integral role when conducting health economic analyses, but a paucity of reference HUVs exists for cancer patients. Using EQ-5D, we generated reference HUVs for multiple malignancies. We further assessed patient willingness to compete the instrument on a regular basis by adding the EQ-5D to an Ontario-wide patient-reported symptom tool mandated by Cancer Care Ontario, the provincial cancer government agency. Methods: 1,831 cancer patients across all non-CNS solid and hematologic cancer sites at the Princess Margaret Cancer Centre completed the EQ-5D instrument; a subset (n=618) were asked about the acceptability of regularly completing the EQ-5D. HUVs were calculated using Canadian valuations. Results: The mean±SD HUV for all patients was 0.81±0.15, but were significantly different across different disease sites (p<0.0001): Testicular cancer, 0.87±0.13; prostate, 0.87±0.15; colorectal, 0.83±0.12; head/neck, 0.82±0.15; lymphoma, 0.82±0.15; breast, 0.81±0.17; esophageal, 0.81±0.16; ovarian, 0.79±0.15; leukemia, 0.78±0.15; lung, 0.78±0.13 and myeloma, 0.77±0.14. Confirming the validity of these HUVs, patients with PRO-ECOG scores of 0, 1, 2 and 3 had HUVs of 0.90±0.14, 0.77±0.11, 0.65±0.14 and 0.59±0.19, respectively (p<0.0001). In patients with solid tumors, those with local disease had HUVs of 0.82±0.15; metastatic disease, 0.80±0.15; p=0.015. 88% of patients reported that the EQ-5D was easy to complete, 92% took less than 5 minutes, 89% were satisfied with its length and 86% were satisfied with the types of questions asked. Importantly, 92% reported that they would complete the EQ-5D, even if it was used solely for research purposes and 73% agreed with the notion of completing it regularly at their clinic visits. Conclusions: We present the first Canadian reference dataset of HUVs for common cancers; stage-and site-specific reference values will be presented at the meeting. Mean HUVs varied by disease site, performance status, and disease severity. Furthermore, a majority of patients surveyed were willing to complete the EQ-5D on a regular basis, suggesting that routine administration is feasible across Ontario.

scholarly journals Estimating Utility value for Female Genital Mutilation

2020 ◽  
Author(s):  
Cyrus Alinia ◽  
Bakhtiar Piroozi ◽  
Fariba Jahanbin ◽  
Hossein Safari ◽  
Amjad Mohamadi-Bolbanabad ◽  
...  
Keyword(s):  
Female Genital Mutilation ◽  
Health Utility ◽  
Utility Value ◽  
Genital Mutilation ◽  
Lower Health ◽  
The Mean ◽  
Socio Demographic Factors ◽  
Female Genital

Abstract Background: Female genital mutilation/cutting (FGM/C) is a clear violation of women's rights and can have adverse and irreversible health effects as well. Worldwide, more than 200 million women and girls have undergone FGM/C. Utility value of FGM/C has not been estimated yet, so we designed this study to extract the health utility value of FGM/C for the first time in the world.Methods: In a cross-sectional study in Iran, 125 girls and women who underwent FGM/C procedure were examined by the trained midwives in order to determine its type. In addition, a questionnaire was completed for identifying the socio-demographic factors and extracting the health utility of these individuals. Health utility was measured using Time Trade-off method and also to determine the effects of the socio-demographic factors on the health utility a two-limit censored regression model was applied.Results: The mean and median of the health utility of women with FGM/C were 0.971 (SE: 0.003) and 0.968 (IQR: 1-0.95), respectively. Number of non-traders was 58 (46.4%) who reported perfect health utility. However, the mean of health utility among traders was 0.946 (SE: 0.002). Only type 1 (Clitoridectomy) and type 2 (Excision) FGM/C were seen in this study. Women with Type 1 FGM/C had significantly lower health utility value (Mean: 0.968, Median: 0.957) than their type 2 counterparts (Mean: 0.987, Median: 1.00). Moreover, women in the age group of 31-45 years (Mean: 0.962, Median: 0.956), single (Mean: 0.950, Median: 0.954), divorced (Mean: 0.951, Median: 0.950), employed (Mean: 0.959, Median: 0.956), and with supplementary insurance (Mean: 0.962, Median: 0.950) had significantly lower health utility than their counterparts.Conclusion: FGM/C affects physical and psychological well-being of these individuals, resulting in a lack of personal and marital satisfaction, which ultimately leads to a 3% reduction in their health related quality of life. Therefore, preventing from this practice is very important and should be considered by health system policy makers more than before.

scholarly journals Health variations among breast-cancer patients from different disease states: Evidence from China

2020 ◽  
Author(s):  
Qing Yang ◽  
Xuexin Yu ◽  
Wei Zhang
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Cancer Recurrence ◽  
Mapping Function ◽  
Health Utility ◽  
Breast Cancer Patients ◽  
Utility Values ◽  
Disease States

Abstract Background: The aim of this study was to obtain health utility data for Chinese breast cancer patients in different disease states to obtain important parameters for health economics modelling and to explore the feasibility of establishing a breast cancer health utility mapping model in China.Methods: Multiple patient-reported health attributes were assessed, including quality of life, which was measured by the Functional Assessment of Cancer Therapy-Breast (FACT-B) instrument; health utility and self-rated health, which were measured by the EuroQol-5 Dimension-5 Level (EQ-5D-5L) questionnaire. Multivariate regression models, including a linear regression model, an ordinal logistic regression model and a Tobit model, were employed to analyse health differences among 446 breast cancer patients. Subgroup analyses were performed to analyse differences in the dimensions of health derived from the FACT-B and EQ-5D-5L instruments. A mapping function was used to estimate health utility from quality of life. Rank correlation analyses were employed to examine the correlation between estimated and observed health utility values.Results: A total of 446 breast cancer patients with different disease states were analysed. The health utility values of breast cancer patients in the P state (without cancer recurrence and metastasis), R state (with cancer recurrence within a year), S state (with primary and recurrent breast cancer for the second year and above), and M state (metastatic cancer) were 0.81 (SD±0.23), 0.90 (SD±0.12), 0.78 (SD±0.31), and 0.74 (SD±0.27), respectively. There were positive correlations between all scores, including each domain of the FACT-B instrument (p<0.001). Multivariate analysis suggested that patients in the R and M states had lower scores for overall quality of life (R, β = -9.45, p< 0.01; M, β = -6.72, p<0.05). Patients in the M state had lower health utility values than patients in the P state (β = -0.11, p< 0.05). Estimated health utility values, which were derived from quality of life using a mapping function, were significantly correlated with directly measured health utility values (p<0.001).Conclusions: We obtained the health utility and health-related quality of life (HRQoL) scores of Chinese breast cancer patients with different disease states. Mapping health utility values from quality of life using four disease states could be feasible in health economic modelling, but the mapping function may need further revision.

scholarly journals Estimating Utility value for Female Genital Mutilation

2020 ◽  
Author(s):  
Cyrus Alinia ◽  
Bakhtiar Piroozi ◽  
Fariba Jahanbin ◽  
Hossein Safari ◽  
Amjad Mohamadi-Bolbanabad ◽  
...  
Keyword(s):  
Female Genital Mutilation ◽  
Health Utility ◽  
Utility Value ◽  
Genital Mutilation ◽  
Lower Health ◽  
The Mean ◽  
Socio Demographic Factors ◽  
Female Genital

Abstract Background: Female genital mutilation/cutting (FGM/C) is a clear violation of women's rights and can have adverse and irreversible health effects as well. Worldwide, more than 200 million women and girls have undergone FGM/C. Utility value of FGM/C has not been estimated yet, so we designed this study to extract the health utility value of FGM/C for the first time in the world. Methods: In a cross-sectional study in Iran, 125 girls and women who underwent FGM/C procedure were examined by the trained midwives in order to determine its type. In addition, a questionnaire was completed for identifying the socio -demographic factors and extracting the health utility of these individuals . Health utility was measured using Time Trade-off method and also to determine the effects of the socio -demographic factors on the health utility a two-limit censored regression model was applied. Findings : The mean and median of the health utility of women with FGM/C were 0.971 (SE: 0.003) and 0.968 (IQR: 1-0.95), respectively . Number of non-traders was 58 (46.4%) who reported perfect health utility. However, the mean of health utility among traders was 0.946 (SE: 0.002). Only type 1 (Clitoridectomy) and type 2 (Excision) FGM/C were seen in this study. Women with Type 1 FGM/C had significantly lower health utility value (Mean: 0.968, Median: 0.957) than their type 2 counterparts (Mean: 0.987, Median: 1.00). Moreover, women in the age group of 31-45 years (Mean: 0.962, Median: 0.956), single (Mean: 0.950, Median: 0.954), divorced (Mean: 0.951, Median: 0.950), employed (Mean: 0.959, Median: 0.956), and with supplementary insurance (Mean: 0.962, Median: 0.950) had significantly lower health utility than their counterparts . Conclusion: FGM/C affects physical and psychological well-being of these individuals, resulting in a lack of personal and marital satisfaction, which ultimately leads to a 3% reduction in their health related quality of life. Therefore, preventing from this practice is very important and should be considered by health system policy makers more than before .

Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 6607-6607
Author(s):  
Mark Doherty ◽  
Yvonne Leung ◽  
Hiten Naik ◽  
Devalben Patel ◽  
Lawson Eng ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Health Utility ◽  
Patient Reported ◽  
Canadian Health ◽  
Utility Scores
Sign in / Sign up

Export Citation Format

Share Document